Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder

Trial Profile

A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms ABACUS
  • Most Recent Events

    • 27 Jan 2024 Results of an exploratory biomarker analysis using different definitions of ctDNA response and assessing correlation with tissue response at time of cystectomy from this trial presented at the 2024 Genitourinary Cancers Symposium
    • 24 Oct 2023 Results assessing the relationship between EFN/EPH expression and response to atezolizumab using data of patients from this study, presented at the 48th European Society for Medical Oncology Congress.
    • 01 Aug 2022 Final results reporting two year data on disease-free and overall survival outcomes and a biomarker analysis assessing novel tissue-based biomarkers and circulating tumor DNA (ctDNA) published in the European Urology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top